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The aging of the general population in developed countries
is becoming a major healthcare issue and it is commonly
addressed as “Silver Tsunami.” Cancer is growing in burden
in elderly patients, as almost 80% of the newly diagnosed
patients are aged over 55 years and the median age at
diagnosis formost neoplastic conditions is over 60 years [1, 2].
Adjunctively, tumor incidence for the population beyond 65
years has increased 11-fold in comparison to younger adults
[3]. Elderly patients represent a peculiar setting for cancer
therapy, with specific characteristics in terms of comorbid
conditions, compliance to treatment, clinical endpoints, and
psychological and social issues. Therefore, the optimal ther-
apeutic strategy for elderly patients represents an intriguing
clinical challenge. Most of the randomized clinical trials did
not enroll older patients because of age limit and particular
comorbid conditions as exclusion criteria [4]. In a recent
survey performedby theEuropeanOrganization forResearch
and Treatment of Cancer (EORTC) and dealing with health-
related quality of life in elderly patients, authors observed
that, among 6000 patients included in 25 trials, only 9% were
aged ≥ 70 [5]. Hence the clinical evidence in this setting
is lacking and most of the guidelines are relatively helpful.
Another interesting aspect is the different perspective on
treatment consequences between older and younger patient
populations as, for example, younger patients seem to con-
sider more worrisome the impact of cancer therapies on
social role functioning and consequent financial issues, while
elderly patients are more focused on items such as impaired
physical functioning, appetite loss, and constipation [5].
Thus, older patients have specific needs and concerns. This
setting of patients also poses several methodological issues
for appropriate clinical management and future trial design.
Compliance to treatment may be different than that of the
general population and drug pharmacokinetics may undergo
age-relatedmodifications, calling for the need of tailored clin-
ical strategies [4]. Hypofractionation schedules reduce acute
toxicity, which can lead to discontinuation of radiotherapy
treatment [6–8]. Appropriate screening tools for geriatric
assessment and biomarkers for aging may strongly help dur-
ing the clinical decision-making process [4]. Consolidated
clinical endpoints, such as survival, may not perfectly fit the
context and should be sustained by items related to quality
of life and patient’s reported outcomes. The oncological
community is gaining awareness on this topic and several
initiatives were set up to fulfil this gap.The Task Force for the
Elderly within the EORTC organization produced a position
paper on the treatment of elderly patients with cancer and
developed a screening tool to distinguish “fit” elderly patients
from fragile cases in order to correctly allocate them to
the most proper treatment strategy [1, 9]. The American
Society of Clinical Oncology (ASCO) formulated, within a
statement paper, 5 recommendations to build up evidence-
based guidelines to guide therapeutic strategy for elderly
patients with cancer [10]. With the present special issue, we
would like to contribute to the growing awareness in the
treatment of cancer in older patients covering a broad range
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of fields of interest, including different therapeutic strategies
(surgery, radiotherapy, chemotherapy, immunotherapy, and
hormonal therapy), treatment tolerance and quality of life,
clinical prognostic factors, biomarkers, and financial and
social implications. The management of elderly patient with
cancer is challenging and articulated, and the quest for the
best option is yet ongoing. The right balance between cure
and care should be the final goal. With this issue, we hope to
help in raising the level of awareness and knowledge on this
topic.
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